Sector News

Pharmaceutical Company Perrigo to acquire German company

July 23, 2015
Life sciences
/PRNewswire/ – Perrigo Company plc (“Perrigo”) PRGO, +1.06% today announced that it has entered into an agreement to acquire Naturwohl Pharma GmbH with its leading German dietary supplement brand, Yokebe. The brand is expected to generate approximately €30 million in full year 2015 net sales. Yokebe, the second largest dietary brand (by market share) in Germany, comes in a shake/liquid form and is marketed within the ‘meal replacement’ category.
 
Perrigo Chairman, President and CEO Joseph C. Papa commented, “Our acquisition of the margin-enhancing Yokebe brand demonstrates our continued execution on our ‘Base Plus Plus Plus’ strategy by building on Omega Pharma’s leading OTC product portfolio and European commercial infrastructure. Coupled with our recent acquisition of well-established European brands from GlaxoSmithKline, we continue to leverage our robust balance sheet and strong global platform to execute immediately accretive deals, such as this one, that will have a multiplier effect on our growth. With Omega’s pan-European distribution network, strong brand-building capabilities and exceptional management team, Perrigo is uniquely positioned to maximize the potential of these brands to capture an even greater share of the $30 billion European OTC market opportunity.”
 
The acquisition is expected to be immediately accretive to Perrigo’s calendar 2015 adjusted earnings per share and to exceed Perrigo’s ROIC threshold in calendar year 2016. The transaction has been unanimously approved by the Boards of Directors of Perrigo and Naturwohl Pharma, and is expected to close in the third quarter, pending German regulatory approval and the satisfaction of customary closing conditions.
 
Source: Perrigo

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”